# Libera Bio S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/libera-bio-s-l

- Industry: Biotechnology
- Headquarters: Galicia, Spain
- Total disclosed funding: $1.4M
- Latest round: Seed (Jan 24, 2022)
- Investors on record: 1

## About

Based in Spain, and founded in 2018 by  María José Alonso (CSO), Desiree Teijeiro (COO), and Olivier Jarry (CEO), Libera Bio S.L., a spin-off of the University of Santiago de Compostela, operates as a preclinical-stage biotechnology company that develops new oncology treatments based on its proprietary MPN technology. In January 2022, Libera Bio S.L. raised EUR 1.3 million in seed funding from investor Xesgalicia, with participation from individual investors.



The firm develops and offers nanotechnology-based therapies that consist of novel antibodies targeting intracellular oncoproteins, tumor and metastatic cells, and delivers small and large molecules to on-surface or intracellular targets to help treat cancer. The firm uses its proprietary technology to target mutated genetics in cancer and develop and offer biopharmaceuticals to help treat cancers that were previously untreated by other methods.

## Funding rounds

- Seed, Jan 24, 2022, $1.4M — Xesgalicia

## Investors

- Xesgalicia (https://capitalatlas.ai/funds/xesgalicia) — Seed